The Alzheimer's Impact Movement (AIM) is a separately incorporated advocacy affiliate of the Alzheimer's Association. AIM advances and develops policies to overcome Alzheimer's disease through increased investment in research, enhanced care and improved support. Thanks to the support of its members, AIM has driven policymakers to take historic steps to address the Alzheimer's crisis — but much more remains to be done.
Today more than 6 million Americans are living with Alzheimer's disease. And, at a cost of $355 billion a year, Alzheimer's is the most expensive disease in the nation. Barring the development of medical breakthroughs to prevent, stop or slow Alzheimer's disease, these numbers will rapidly increase.
It is because of this trajectory and the impact of the disease on families that AIM works to advance public policies to enhance care and support, as well as to accelerate research.
As a 501(c)(4), AIM is able to engage with lawmakers in all elements of their job — including activities considered electoral or political — to keep the Alzheimer's community and our issues top-of-mind with elected officials.
AIM impresses upon our elected officials the growing crisis Alzheimer's presents to our nation's families and the economy. In doing so, AIM is inspiring these leaders to take bold action to address Alzheimer's.
AIM amplifies the voice of Alzheimer's Association advocates — to lend them even more power. AIM carries this message to halls of Congress on behalf of the hundreds of thousands of Alzheimer's advocates across the country.
Examples of what AIM can and has done include:
The Alzheimer’s Impact Movement (AIM), a separately incorporated advocacy affiliate of the Alzheimer’s Association, forges partnerships with all those who share the same commitment to end Alzheimer’s and all other dementia. That includes other Alzheimer’s organizations, organizations in the aging space, the National Institutes of Health, the National Institute on Aging, universities, corporations and the pharmaceutical, biotech and device industries. With our broad partnerships, we are committed to transparency.
We work with ethical companies, organizations and individuals who share our mission and can help achieve a world without Alzheimer’s and all other dementia while maintaining independence and actively safeguarding against outside influence. Importantly, no contribution from, or partnership with any entity or individual impacts AIM decision-making, nor our positions on issues related to people living with Alzheimer’s, other dementia and their families. This section is dedicated to transparent sharing of financial and partnership information with all constituents.
Thanks to the combined work of AIM and the Alzheimer's Association, our community has celebrated historic advancements in Alzheimer's public policy. Together, and with the tireless work of our advocates, we have:
Together with our advocates, we advanced the Promoting Alzheimer’s Awareness to Prevent Elder Abuse Act to protect people with dementia from elder abuse.
AIM and the Alzheimer's Association championed the Improving HOPE for Alzheimer's Act to educate providers and increase utilization of critical care planning services available through Medicare.
Advocated for federal Alzheimer's and dementia research funding increases Grew support for a $300 million Alzheimer’s and dementia research funding increase at the NIH. Today, federal funding is $3.1 billion annually, representing a more than seven-fold increase in research funding since NAPA passed.
Built bipartisan support for the Younger-Onset Alzheimer's Disease Act, which ensures Americans living with dementia under the age of 60 can now utilize nutritional services, supportive services, and respite care through the National Family Caregiver Support program.
Worked with bipartisan Congressional champions to secure an additional $350 million in federal research funding. Today funding for Alzheimer's and dementia research at the National Institutes of Health (NIH) is $2.8 billion annually, and representing a more than six-fold increase in research funding since the passage of the National Alzheimer's Project Act.
Developed and worked with Congressional champions to pass the BOLD Infrastructure for Alzheimer's Act, critical legislation to addressing Alzheimer's as a public health issue.
Worked with House and Senate bipartisan champions to secure the largest increase in federal funding for Alzheimer's research at the National Institutes of Health, for the fourth year in a row — a $425 million increase in fiscal year 2019.
Grew support for Kevin & Avonte's Law, a bipartisan bill to protect seniors with Alzheimer's and dementia and children with developmental disabilities who are prone to wandering.
Worked to secure an extension of the Independence at Home (IAH) demonstration model through 2019. The IAH demonstration model provides Medicare beneficiaries with multiple, complex chronic conditions with specialized care at home from a team of healthcare providers.
Supported and advocated for the RAISE Family Caregivers Act which requires the Department of Health and Human Services (HHS) to develop, maintain and periodically update a National Family Caregiving Strategy.
Made Alzheimer's a national priority on the 2016 campaign trail. Alzheimer's became an issue at candidate debates, in candidate's advertising, and for the first time in our nation's history, an incoming president has declared Alzheimer's disease would be a priority of his administration.
Worked with state governments to create State Alzheimer's Plans in nearly every state.
Conceived of and championed the HOPE for Alzheimer's Act to provide Medicare coverage for comprehensive care planning services for those living with Alzheimer's disease and other cognitive impairments. Because of our efforts, congressional cosponsorship soared, and in November 2016, the Centers for Medicare & Medicaid Services (CMS) finalized a decision to pay for cognitive and functional assessments and care planning.
Supported the 21st Century Cures Act to bolster medical research to accelerate the discovery, development and delivery of new treatments and cures for Alzheimer's and other diseases.
Created the concept of the Alzheimer's Accountability Act (AAA). Once introduced, AIM and the Association were the only organizations to lobby in support of the bill which was enacted into law that same year. AAA and has transformed discussions about Alzheimer's research funding on Capitol Hill.
Developed with Congress the National Alzheimer's Project Act (NAPA), resulting in the first National Plan to Address Alzheimer's Disease with the goal of preventing and effectively treating Alzheimer's by 2025.
Ensured people living with Younger-Onset Alzheimer’s and dementia have access to critical care and support services through the Older Americans Act, regardless of their age.